Acadia Pharmaceuticals | ACAD - Ebitda


Acadia Pharmaceuticals reported $20.31M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
ALKERMES USD 80.26M 20.05M Mar/2026
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Corcept Therapeutics USD 4.2M 6.5M Dec/2025
Cytokinetics USD -169.32M 19.48M Mar/2026
Eisai JPY -335M 30.43B Mar/2026
Eli Lilly USD 12.14B 4.26B Dec/2025
Incyte USD 367.97M 46.53M Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Moderna USD -790M 582M Dec/2025
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Prothena USD 25.98M 65.51M Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026